Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

Leukocare AG. (3/1/21). "Press Release: Leukocare and Malvern Collaborate on Stabilization and Formulation Development of COVID-19 Vaccines". Martinsried & Malvern.

Organisations Organisation Leukocare AG
  Group Leukocare (Group)
  Organisation 2 Malvern Panalytical Ltd.
  Group Spectris (Group)
Products Product drug delivery technology (drug formulation technology)
  Product 2 vaccine, SARS-CoV-2 (COVID-19)
Persons Person Seidl, Andreas (Leukocare 202103 COO)
  Person 2 Ströver, Rebekka (Leukocare 202103 Specialist Communications + Marketing)

> Malvern Panalytical to support Leukocare in its formulation development projects on Covid-19 vaccine stabilization

> Combining profound knowhow and analytical expertise to improve stability of Covid-19 vaccines

Leukocare AG and Malvern Panalytical Ltd today announced an exciting collaboration which will improve the availability of vaccines for COVID-19. They will combine Leukocare’s pioneering expertise in biopharmaceutical formulation development with Malvern Panalytical’s extensive analytical knowhow to understand how the stability of vaccines can be improved, increasing production and simplifying distribution.

Dr. Andreas Seidl, Chief Operating Officer at Leukocare, commented, “I am excited and thankful to start this collaboration in these unprecedented times. While we have already seen tremendous efforts and several successes on approvals of vaccines targeting the COVID-19 pandemic in the past few months, there still is a high unmet need for improved stability, supply and storage conditions to serve the vast majority of people and countries over the upcoming months and years. Our collaboration with Malvern Panalytical will help us to work even better on our ongoing and future projects to achieve stability improvements for a range of vaccines.”

Mark Fleiner, President of Malvern Panalytical, also expressed excitement about the opportunities presented by this project. “We have all experienced the impact of the current COVID-19 pandemic on the lives of our families, friends and work colleagues” stated Mark. “The availability of vaccines brings hope to us all – so we jumped at the opportunity to be involved in this deep collaboration with Leukocare working together to understand how vaccine stability can be improved and ensure wider availability.”

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence. The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product’s needs. Leukocare’s superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

About the technology

Profiling and optimization of colloidal and thermal stability of biologics is at the center of Malvern Panalytical’s technical solutions and expertise, with Dynamic Light Scattering, multi-detector size-exclusion chromatography, and Differential Scanning Calorimetry (DSC) providing the complementary data required to drive formulation development. MicroCal DSC is a gold standard technique for assessing thermal stability and facilitating the selection of stable formulations and has been used in the development of a wide range of biologics from recombinant proteins and vaccines to viral vectors and lipid-based drug delivery systems.

About Malvern Panalytical

When you make the invisible visible, the impossible is possible. Our scientific instruments and solutions help our customers to create a better world. Through chemical, physical and structural analysis of materials, they improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy. We partner with many of the world’s biggest companies, universities and research organizations. They value us not only for the power of our solutions, but also for the depth of our expertise, collaboration and integrity.

Our roots

Once, we were two companies: Malvern Instruments and PANalytical. Now we are one, with over 2,200 people worldwide, and part of Spectris plc, the world-leading precision measurements Group.



Dr. Andreas Seidl
+ 49 (0) 89 7801 6650

Rebekka Ströver
Specialist Communications & Marketing
+ 49 (0) 89 7801 665 14

Malvern Panalytical

Isabelle Kuper-Borsboom
Global Communications Manager
+31 (0) 6 10560274

Record changed: 2021-10-22


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for Leukocare (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

» top